Norges Bank I Teos Therapeutics, Inc. Transaction History

Norges Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2023	BUY	$31.92 - $47.45 $1.68 Million - $2.49 Million	52,500 New	52,500 $1.69 Million
Q1 2022 May 09, 2022	SELL	$31.92 - $47.45 $1.68 Million - $2.49 Million	-52,500 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$26.23 - $47.86 $1.38 Million - $2.51 Million	52,500 New	52,500 $2.44 Million
Q4 2020 Feb 10, 2021	SELL	$21.59 - $33.95 $1.14 Million - $1.8 Million	-53,000 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$17.57 - $32.92 $931,210 - $1.74 Million	53,000 New	53,000 $1.31 Million

166

36.6M

1.95M

374K

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $266M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.